Induction of STAT3-dependent CXCL5 expression and neutrophil recruitment by oncostatin-M during pneumonia

American Journal of Respiratory Cell and Molecular Biology

Volumn 53, Issue 4, 2015, Pages 479-488

  Traber, Katrina E ^a   Hilliard, Kristie L ^a   Allen, Eri ^a   Wasserman, Gregory A ^a   Yamamoto, Kazuko ^a,b   Jones, Matthew R ^a   Mizgerd, Joseph P ^a   Quinton, Lee J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

CXCL5; Macrophage; Neutrophil; Oncostatin M; Pneumonia; STAT3

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CXCL5 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ARTICLE; CYTOKINE RESPONSE; ESCHERICHIA COLI; ESCHERICHIA COLI PNEUMONIA; HOST RESISTANCE; IN VIVO STUDY; INNATE IMMUNITY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM CELL; LUNG LAVAGE; LUNG LOBE; MACROPHAGE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PROTEIN EXPRESSION; ANIMAL; BACTERIAL PNEUMONIA; C57BL MOUSE; ESCHERICHIA COLI INFECTION; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CXCL5; ESCHERICHIA COLI INFECTIONS; GENE EXPRESSION; HUMANS; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; ONCOSTATIN M; PNEUMONIA, BACTERIAL; RESPIRATORY MUCOSA; STAT3 TRANSCRIPTION FACTOR;

EID: 84942895201     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0342OC     Document Type: Article

References (43)

1. Mizgerd JP. Lung infection: a public health priority. PLoS Med 2006;3: e76.
2. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010;362:1804-1813.
3. Cohen J. Confronting the threat of multidrug-resistant gram-negative bacteria in critically ill patients. J Antimicrob Chemother 2013;68:490-491.
4. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008; 358:716-727.
5. Bhan U, Cornicelli MD, Standiford TJ. Cytokine networks in the infected lung. Expert Rev Respir Med 2008;2:739-752.
6. Quinton LJ, Mizgerd JP. Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling. Annu Rev Physiol 2015;77: 407-430.
7. Quinton LJ, Blahna MT, Jones MR, Allen E, Ferrari JD, Hilliard KL, Zhang X, Sabharwal V, Algül H, Akira S, et al. Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J Clin Invest 2012;122:1758-1763.
8. Ahyi AN, Quinton LJ, Jones MR, Ferrari JD, Pepper-Cunningham ZA, Mella JR, Remick DG, Mizgerd JP. Roles of STAT3 in protein secretion pathways during the acute-phase response. Infect Immun 2013;81: 1644-1653.
9. Quinton LJ, Mizgerd JP. NF-κB and STAT3 signaling hubs for lung innate immunity. Cell Tissue Res 2011;343:153-165.
10. Quinton LJ, Jones MR, Robson BE, Simms BT, Whitsett JA, Mizgerd JP. Alveolar epithelial STAT3, IL-6 family cytokines, and host defense during Escherichia coli pneumonia. Am J Respir Cell Mol Biol 2008;38:699-706.
11. Quinton LJ, Mizgerd JP, Hilliard KL, Jones MR, Kwon CY, Allen E. Leukemia inhibitory factor signaling is required for lung protection during pneumonia. J Immunol 2012;188:6300-6308.
12. Jones MR, Quinton LJ, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Roles of interleukin-6 in activation of STAT proteins and recruitment of neutrophils during Escherichia coli pneumonia. J Infect Dis 2006; 193:360-369.
13. Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, Marquardt H, Zarling JM, Shoyab M, Wei CM, et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 1989;9: 2847-2853.
14. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci USA 1986;83: 9739-9743.
15. Pelletier JP, Martel-Pelletier J. Oncostatin M: foe or friend? Arthritis Rheum 2003;48:3301-3303.
16. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003;149:39-52.
17. Richards CD. The enigmatic cytokine oncostatin M and roles in disease. ISRN Inflammation 2013;2013:512103.
18. Nagahama KY, Togo S, Holz O, Magunussen H, Liu X, Seyama K, Takahashi K, Rennard SI. Oncostatin M modulates fibroblast function via STAT3. Am J Respir Cell Mol Biol 2013;49:582-591.
19. Mozaffarian A, Brewer AW, Trueblood ES, Luzina IG, Todd NW, Atamas SP, Arnett HA. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 2008;181:7243-7253.
20. Scaffidi AK, Mutsaers SE, Moodley YP, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 2002;136:793-801.
21. O'Hara KA, Kedda MA, Thompson PJ, Knight DA. Oncostatin M: an interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma. Clin Exp Allergy 2003;33:1026-1032.
22. Grenier A, Combaux D, Chastre J, Gougerot-Pocidalo MA, Gibert C, Dehoux M, Chollet-Martin S. Oncostatin M production by blood and alveolar neutrophils during acute lung injury. Lab Invest 2001;81: 133-141.
23. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
24. Quinton LJ, Jones MR, Robson BE, Mizgerd JP. Mechanisms of the hepatic acute-phase response during bacterial pneumonia. Infect Immun 2009;77:2417-2426.
25. Mei J, Liu Y, Dai N, Favara M, Greene T, Jeyaseelan S, Poncz M, Lee JS, Worthen GS. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 2010;33: 106-117.
26. Theivanthiran B, Batra S, Balamayooran G, Cai S, Kobayashi K, Flavell RA, Jeyaseelan S. NOD2 signaling contributes to host defense in the lungs against Escherichia coli infection. Infect Immun 2012;80: 2558-2569.
27. Yamamoto K, Ferrari JD, Cao Y, Ramirez MI, Jones MR, Quinton LJ, Mizgerd JP. Type I alveolar epithelial cells mount innate immune responses during pneumococcal pneumonia. J Immunol 2012;189: 2450-2459.
28. Yamamoto K, Ahyi AN, Pepper-Cunningham ZA, Ferrari JD, Wilson AA, Jones MR, Quinton LJ, Mizgerd JP. Roles of lung epithelium in neutrophil recruitment during pneumococcal pneumonia. Am J Respir Cell Mol Biol 2014;50:253-262.
29. Dey G, Radhakrishnan A, Syed N, Thomas JK, Nadig A, Srikumar K, Mathur PP, Pandey A, Lin SK, Raju R, et al. Signaling network of Oncostatin M pathway. J Cell Commun Signal 2013;7:103-108.
30. Wong S, Botelho FM, Rodrigues RM, Richards CD. Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 dysregulation in lungs of fibrosis-resistant BALB/c mice. Lab Invest 2014;94:1003-1016.
31. Cai S, Batra S, Lira SA, Kolls JK, Jeyaseelan S. CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. J Immunol 2010;185:6214-6225.
32. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Laichalk LL, McGillicuddy DC, Standiford TJ. Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 1996; 173:159-165.
33. Jeyaseelan S, Manzer R, Young SK, Yamamoto M, Akira S, Mason RJ, Worthen GS. Induction of CXCL5 during inflammation in the rodent lung involves activation of alveolar epithelium. Am J Respir Cell Mol Biol 2005;32:531-539.
34. McQualter JL, Yuen K, Williams B, Bertoncello I. Evidence of an epithelial stem/progenitor cell hierarchy in the adult mouse lung. Proc Natl Acad Sci USA 2010;107:1414-1419.
35. Suda T, Chida K, Todate A, Ide K, Asada K, Nakamura Y, Suzuki K, Kuwata H, Nakamura H. Oncostatin M production by human dendritic cells in response to bacterial products. Cytokine 2002;17: 335-340.
36. Grenier A, Dehoux M, Boutten A, Arce-Vicioso M, Durand G, Gougerot-Pocidalo MA, Chollet-Martin S. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood 1999;93:1413-1421.
37. Cichy J, Rose-John S, Travis J. Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alpha1-proteinase inhibitor synthesis in human lung-derived epithelial cells. Biochem J 1998;329:335-339.
38. Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, Topley N, Jones SA. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J Immunol 2002;169:5244-5251.
39. Jeyaseelan S, Chu HW, Young SK, Worthen GS. Transcriptional profiling of lipopolysaccharide-induced acute lung injury. Infect Immun 2004;72:7247-7256.
40. Wuyts A, D'Haese A, Cremers V, Menten P, Lenaerts JP, De Loof A, Heremans H, Proost P, Van Damme J. NH2- and COOH-terminal truncations of murine granulocyte chemotactic protein-2 augment the in vitro and in vivo neutrophil chemotactic potency. J Immunol 1999;163:6155-6163.
41. Fritz DK, Kerr C, Fattouh R, Llop-Guevara A, Khan WI, Jordana M, Richards CD. A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. J Immunol 2011;186: 1107-1118.
42. Lafontant PJ, Burns AR, Donnachie E, Haudek SB, Smith CW, Entman ML. Oncostatin M differentially regulates CXC chemokines in mouse cardiac fibroblasts. Am J Physiol Cell Physiol 2006;291: C18-C26.
43. Hol J, Wilhelmsen L, Haraldsen G. The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies. J Leukoc Biol 2010;87:501-508.